Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor

Cancer Science

Volumn 97, Issue 3, 2006, Pages 183-191

  Nakataki, Emiko ^a   Yano, Seiji ^a   Matsumori, Yuka ^a   Goto, Hisatsugu ^a   Kakiuchi, Soji ^a   Muguruma, Hiroaki ^a   Bando, Yoshimi ^a   Uehara, Hisanori ^a   Hamada, Hironobu ^b   Kito, Katsumi ^b   Yokoyama, Akihito ^c   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SENSITIVITY; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MALIGNANT MESOTHELIOMA; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURA METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THORAX CANCER; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PLEURAL NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645990895     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00163.x     Document Type: Article

References (45)

1. Light RW. Pleural Diseases, 4th edn. Philadelphia: Lippincott, Williams and Wilkins, 2001.
2. Broaddus VC. Asbestos, the mesothelial cell and malignancy: A matter of life or death. Am J Respir Cell Mol Biol 1997; 17: 657-9.
3. Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, Sera Y. Asbestos-related lung cancer and mesothelioma in Japan. Industrial Health 2001; 39: 65-74.
4. Mineral fiber content of lungs in patients with mesothelioma seeking compensation in Quebec. Am J Respir Crit Care Med 1996; 153: 711-18.
5. Hoffman RM. Patient-like models of human cancer in mice. A review and critique of their development. Curr Perspect Mol Cell Oncol 1992; 1: 311-29.
6. Yokoyama A, Kohno N, Fujino S et al. Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions. Oncol Rep 1994; 1: 507-11.
7. Yano S, Shinohara H, Herbst RS et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 2000; 157: 1893-903.
8. Green LM, Reade JL, Ware CF. Rapid colometric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Meth 1984; 70: 257-68.
9. Yano S, Shinohara H, Herbst RS et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000; 60: 4959-67.
10. Dias S, Hattori K, Zhu Z et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000; 106: 511-21.
11. Shushanov S, Bronstein M, Adelaide J et al. VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer 2000; 86: 47-52.
12. Yano S, Shinohara H, Herbst RS et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000; 60: 4959-67.
13. Rosai J. Rosao and Ackerman's Surgical Pathology, 9th edn. New York: Mosby, 2004.
14. Ferrara N. The role of vascular endothelial growth factor in the regulation of blood vessel growth. In: Bicknell R, Lewis CE, Ferrara N, eds. Tumor Angiogenesis. New York: Oxford University Press, Inc., 1997; 185-99.
15. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.
16. Shibuya M, Yamaguchi S, Yamane A et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519-24.
17. Terman BI, Dougher-Vermazen M, Carrion ME et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-86.
18. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 1991; 88: 9026-30.
19. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999; 17: 25-30.
20. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002; 12: 89-96.
21. Miyoshi T, Kondo K, Ishikura H, Kinoshita H, Matsumori Y, Monden Y. SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. Anticancer Res 2000; 20: 161-3.
22. Fu X, Le P, Hoffman RM. A metastatic orthotopic-transplant nude-mouse model of human patient breast cancer. Anticancer Res 1993; 13: 901-4.
23. Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M, Hoffman RM. Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res 1993; 53: 1204-8.
24. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 1988; 48: 6863-71.
25. Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 1986; 46: 4109-15.
26. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 1992; 89: 5645-9.
27. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992; 84: 951-7.
28. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726-34.
29. Lee JM, Bruckner HW, Szrajer L, Brenne U, Schindelheim G, Andreotti PE. Taxol inhibits growth of mesothelioma xenografts. Anticancer Res 1995; 15: 693-6.
30. Smythe WR, Hwang HC, Elshami AA et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995; 222: 78-86.
31. Colt HG, Astoul P, Wang X, Yi ES, Boutin C, Hoffman RM. Clinical course of human epithelial-type malignant pleural mesothelioma replicated in an orthotopic-transplant nude mouse model. Anticancer Res 1996; 16: 633-9.
32. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003; 27: 1031-51.
33. Versnel MA, Claesson-Welsh L, Hammacher A et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 1991; 6: 2005-11.
34. Lee TC, Zhang Y, Aston C et al. Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 1993; 53: 2858-64.
35. Morocz IA, Schmitter D, Lauber B, Stahel RA. Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. Br J Cancer 1994; 70: 850-6.
36. Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. Interleukin 8: An autocrine growth factor for malignant mesothelioma. Cancer Res 1999; 59: 367-71.
37. Ohta Y, Shridhar V, Bright RK et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999; 81: 54-61.
38. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
39. Konig JE, Tolnay E, Wiethege T, Muller KM. Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer 1999; 85: 2570-6.
40. Strizzi L, Catalano A, Vianale G et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001; 193: 468-75.
41. Konig J, Tolnay E, Wiethege T, Muller K. Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma. Respiration 2000; 67: 36-40.
42. Zebrowski BK, Yano S, Liu W et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999; 5: 3364-8.
43. Yano S, Herbst RS, Shinohara H et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000; 6: 957-65.
44. Byrne MJ, Davidson JA, Musk AW et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 1999; 17: 25-30.
45. Hazarika M, White RM Jr, Booth BP et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005, 2005; 11: 982-92.